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Abstract
Background: Vascular Cognitive Impairment (VCI) refers to cognitive dysfunction due to vascular brain injury, as a single
cause or in combination with other, often neurodegenerative, etiologies. VCI is a broad construct that captures a heterogeneous
patient population both in terms of cognitive and noncognitive symptoms and in terms of etiology and prognosis. This provides
a challenge when applying this construct in clinical practice.
Objective: This paper presents the rationale and design of the TRACE-VCI study, which investigates the clinical features and
prognosis of VCI in a memory clinic setting.
Methods: The TRACE-VCI project is an observational, prospective cohort study of 861 consecutive memory clinic patients
with possible VCI. Between 2009 and 2013, patients were recruited through the Amsterdam Dementia Cohort of the VU University
Medical Centre (VUMC) (N=665) and the outpatient memory clinic and VCI cohort of the University Medical Centre Utrecht
(UMCU) (N=196). We included all patients attending the clinics with magnetic resonance imaging (MRI) evidence of vascular
brain injury. Patients with a primary etiology other than vascular brain injury or neurodegeneration were excluded. Patients
underwent an extensive 1-day memory clinic evaluation including an interview, physical and neurological examination, assessment
of biomarkers (including those for Alzheimer-type pathologies), extensive neuropsychological testing, and an MRI scan of the
brain. For prognostic analyses, the composite primary outcome measure was defined as accelerated cognitive decline (change of
clinical dementia rating ≥1 or institutionalization) or (recurrent) major vascular events or death over the course of 2 years.
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Results: The mean age at baseline was 67.7 (SD 8.5) years and 46.3% of patients (399/861) were female. At baseline, the median
Clinical Dementia Rating was 0.5 (interquartile range [IQR] 0.5-1.0) and the median Mini-Mental State Examination score was
25 (IQR 22-28). The clinical diagnosis at baseline was dementia in 52.4% of patients (451/861), mild cognitive impairment in
24.6% (212/861), and no objective cognitive impairment in the remaining 23.0% (198/861).
Conclusions: The TRACE-VCI study represents a large cohort of well-characterized patients with VCI in a memory clinic
setting. Data processing and collection for follow-up are currently being completed. The TRACE-VCI study will provide insight
into the clinical features of memory clinic patients that meet VCI criteria and establish key prognostic factors for further cognitive
decline and (recurrent) major vascular events.
(JMIR Res Protoc 2017;6(4):e60)   doi:10.2196/resprot.6864
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Introduction
Cerebral vascular injury is a common cause of dementia and
milder forms of cognitive dysfunction [1]. This vascular burden
in cognitive decline and dementia is referred to as vascular
cognitive impairment (VCI) [2,3]. According to the current
literature, the concept or construct of VCI covers the entire
spectrum of cognitive disorders ranging from mild cognitive
impairment (MCI) through fully developed dementia, due to all
forms of vascular brain injury [4]. It includes vascular disease
as a single etiology, but also in combination with other, often
neurodegenerative, causes of cognitive impairment [3,4].
VCI is thus a broad construct that captures a heterogeneous
patient population both in terms of cognitive and noncognitive
symptoms and in terms of etiology and prognosis. In clinical
practice, VCI is mainly observed in stroke (in- and outpatient)
services and in memory clinics (ie, outpatient cognitive
impairment and dementia diagnostic centers). In a stroke clinic
setting, mild to severe cognitive deficits may manifest
themselves acutely or delayed after an ischemic or hemorrhagic
stroke, in which case it is generally straightforward to establish
a causal link between the vascular event and the cognitive
deficit. In a memory clinic setting, patients more often present
with insidious cognitive changes evolving over the course of
many years. Vascular injury in these patients most commonly
involves small vessel disease [5]. In many cases, multiple
vascular lesions co-exist and often also co-occur with
neurodegenerative pathologies, in particular Alzheimer’s disease
[3,4]. These mixed pathologies can make it more challenging
to establish causality between the vascular lesions and the
cognitive deficits in individual patients. In fact, there are no
validated and generally accepted thresholds at which visible
vascular brain injury can be considered “clinically relevant” in
a patient presenting at a memory clinic. Moreover, it is still
unclear to which extent vascular injury determines prognosis
in a memory clinic setting, particularly when it co-occurs with
other etiologies [6]. Addressing these uncertainties is important,
given the frequent occurrence of vascular lesions in memory
clinic patients. Yet, there are few studies on VCI in memory
clinic cohorts [7].
The overall aim of the “Utrecht-Amsterdam clinical features
and prognosis in vascular cognitive impairment” (TRACE-VCI)
study is to establish the relation between different patterns of
cerebral vascular injury and the cognitive profile and prognosis
of patients in a memory clinic setting. We want to establish
which clinical features of patients cluster in particular VCI
phenotypes. In addition, we aim to identify key prognostic
factors for further cognitive decline and/or (recurrent) major
vascular events. To this end, we prospectively collected data of
all patients with cognitive complaints and any burden of vascular
brain injury on magnetic resonance imaging (MRI) from our
memory clinics between 2009 and 2013. When this study was
initiated, the construct of VCI had been introduced [2,3], but
widely accepted clinical criteria for VCI were still lacking. In
the absence of applicable VCI criteria, we intentionally
developed nonrestrictive inclusion criteria for our study. We
did not define minimal thresholds for cognitive impairment or
specific patterns of vascular brain injury, in order to capture the
whole spectrum of patients presenting at a memory clinic with
cognitive complaints and visible vascular injury on MRI. We
also did not select patients based on evidence for absence or
presence of other neurodegenerative etiologies. This approach
allowed us to study the full spectrum of cognitive disorders in
relation to vascular brain injury as seen in a memory clinic and
detect critical thresholds for clinically relevant vascular injury
in this setting. Further subdivisions or selections according to
stages of cognitive impairment, specific burden of vascular
injury, and co-occurring pathologies will be applied as part of
the analytic strategy of the TRACE-VCI study. This paper
describes the design and protocol of the study including the
baseline characteristics of the study population.
Methods/Design
Study Design
The TRACE-VCI study is a prospective observational follow-up
study of 861 consecutive memory clinic patients from three
Dutch outpatient clinics at two university hospitals. These
tertiary referral clinics receive referrals from specialists from
other memory clinics (eg, for a second opinion) but also direct
referrals from general practitioners. Subjects were included
from the outpatient clinic of the VU University Medical Centre
(VUMC), registered in the Amsterdam Dementia Cohort
(N=665) and from the two outpatient memory clinics of the
University Medical Centre Utrecht (UMCU) (N=196) [8,9].
Patients with cognitive complaints and any burden of vascular
brain injury on MRI (inclusion criteria are specified below)
were prospectively included at their first visit to the clinics
between September 2009 and December 2013. Each patient
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received a standardized extensive 1-day memory clinic
evaluation including an interview, physical and neurological
examination, laboratory testing, extensive neuropsychological
testing, and an MRI scan of the brain [4]. The study was
approved by the institutional review board of the VUMC and
the UMCU. All patients provided informed consent prior to
research related procedures.
Follow-up investigation was performed around 2 years from
baseline visit. Primary outcome variable for the prognostic
studies was cognitive decline and/or (recurrent) major vascular
events. These outcome variables are described in detail in the
follow-up investigation section.
Study Objectives
The main objectives of the TRACE-VCI study are:
1. To establish the clinical features of memory clinic patients
with vascular brain injury on MRI, addressing the following
questions:
• What are the patterns of vascular brain injury on MRI?
• What are the cognitive profiles of the patients and how
does the nature and severity of vascular brain injury
relate to these profiles?
• How does vascular brain injury relate to noncognitive
outcomes, for example, depression, gait, and falls?
• How do vascular brain injury and co-existent
neurodegenerative disease interact?
• Which features cluster in particular VCI phenotypes?
2. To identify key prognostic factors in patients with possible
VCI at a memory clinic:
• Which factors predict further cognitive decline or
(recurrent) major vascular events?
• Can poor outcome be reliably predicted on an individual
basis?
Inclusion Criteria
We included patients with possible VCI with minimal constraints
in terms of cognitive impairment and vascular brain injury. The
presence of other co-occurring etiologies, such as
neurodegenerative disease or depression was accepted because
many patients with VCI have neurodegenerative disease as a
comorbid etiology and depression can be a manifestation of
cerebrovascular disease [3,10]. According to this rationale,
possible VCI was defined according to the following criteria in
the TRACE-VCI study.
Cognitive Impairment
Patients were included in the TRACE-VCI study regardless of
the severity of cognitive impairment. The only criterion was
that people had to be referred to the memory clinic because of
suspected cognitive impairment. Patients were divided in three
categories related to the extent of cognitive impairment:
dementia, mild cognitive impairment (MCI), and a third group
with no objective cognitive impairment (NOCI). The rationale
for including patients with NOCI (also referred to as subjective
cognitive impairment in memory clinics [11]) is that some
patients with cognitive complaints and cognitive dysfunction
due to vascular brain injury may not meet formal criteria for
cognitive impairment on psychometric testing. We therefore
decided to include all patients with cognitive complaints and
evidence of vascular brain injury in the cohort and address
different categories of cognitive impairment in the analyses.
Vascular Brain Injury
Any patient with at least a minimal burden of vascular brain
injury on MRI was eligible for TRACE-VCI. As for cognition,
we deliberately did not specify a threshold of injury. Moreover,
we included patients regardless of the judgment of the treating
physician on the clinical relevance of the vascular brain injury.
To be included in TRACE-VCI, patients had to show at least
one of the following forms of vascular brain injury on MRI,
rated according to established criteria (Table 1) [12]:
1. white matter hyperintensities (WMH) with a Fazekas scale
[13] grade ≥2
2. Fazekas scale grade 1 and an increased vascular risk defined
as the presence of ≥2 vascular risk factors (hypertension,
hypercholesterolemia, diabetes mellitus, obesity, current
smoking, or a reported history of a vascular event other
than stroke)
3. ≥1 lacunar infarct(s)
4. ≥1 nonlacunar infarct(s)
5. ≥1 cerebral microbleed(s)
6. ≥1 intracerebral hemorrhage
Table 1. Entry criteria for vascular brain injurya.
Single vascular injury only, n
(N=510)
Mixed or single vascular injury, n
(N=861)
Vascular brain injury
210307Fazekas score 1 and ≥2 vascular risk factors
160399Fazekas score 2 or 3
13188≥1 Lacunar infarct(s)
483≥1 Nonlacunar infarct(s)
120368≥1 Microbleed(s) (N=849)
316≥1 Intracerebral hemorrhage(s)
aIf there were missing data, the number (n=) is specifically mentioned.The first column presents the proportion of patients meeting the different entry
criteria of vascular brain injury, either as a single criterion or in combination with others. The second column lists only patients who presented with a
single category of vascular brain injury markers.
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For criterion 2, the presence of hypertension was determined
based on a self-reported medical history, use of antihypertensive
drugs, or a newly diagnosed hypertension defined as a blood
pressure of 140/90 mmHg or more, measured by means of a
sphygmomanometer [14]. Hypercholesterolemia was determined
based on medical history or medication use. Diabetes mellitus
was based on medical history or medication use. Glucose or
HbA1c levels were available from 96.9% (834/861) of patients.
Patients were classified as newly diagnosed diabetes mellitus
if they had a nonfasting glucose of ≥11.1 mmol/l or an HbA1c
≥48 mmol/mol (or ≥6.5%) [15]. Obesity was defined as a
baseline body mass index (BMI) ≥30, calculated as weight in
kilograms divided by height in meters squared. A self-reported
history of a vascular event other than stroke was defined as a
history of ischemic heart disease (myocardial infarction, surgery,
or endovascular treatment for coronary artery disease) [16],
peripheral arterial disease (any arterial occlusion or surgical
intervention of a peripheral artery such as an abdominal or leg
artery), and carotid artery stenting.
Exclusion Criteria
Patients with a monogenic nonvascular or vascular cause of
cognitive dysfunction were excluded from the study population.
These genetic diseases are relatively rare and have a distinct
disease profile, which is in many aspects different from the
other patients in this cohort. Patients with other nonvascular
and nondegenerative primary causes of cognitive dysfunction
such as a brain tumor, extensive traumatic head injury, substance
or alcohol abuse, and multiple sclerosis were also excluded.
Finally, patients with psychiatric diseases, other than depression,
resulting in cognitive dysfunction were excluded.
Interview and Physical and Neurological Examination
Patients received a standardized diagnostic assessment
performed by a neurologist or geriatrician including an interview
on cognitive complaints and medical history, medication use
(verified through listings provided by pharmacy), educational
level, smoking, alcohol and drug abuse, family medical history,
and social status. Patients were asked to bring a relative or good
friend for an informant interview. Table 2 shows demographic
characteristics and vascular risk factors of the study population.
Table 2. Demographic characteristics and vascular risk factors in the TRACE-VCI study.
Patients
(N=861)
Demographic characteristics
399 (46.3)Female, n (%)
67.7 (8.5)Age in years, mean (SD)
5 (4-6)Level of education (Verhage scale range 1-7)a (N=856), median (IQR)
Vascular risk factors, n (%)
729 (84.7)Hypertension
499 (68.4)Medical history/use of medication
230 (31.6)Newly diagnosed hypertension (>140/90mmHg) (N=834)
386 (44.8)Hypercholesterolemia
169 (19.6)Diabetes mellitus
146 (86.4)Medical history/ use of medication
23 (13.6)Newly diagnosed diabetes mellitus (N=834)
173 (20.1)Current smoker (N=853)
176 (20.4)Obesity (BMI ≥30) (N=848)
History of reported vascular events, n (%)
78 (9.1)History of reported stroke
86 (10.0)History of reported vascular events other than stroke
60 (69.8)History of ischemic heart diseaseb
4 (4.7)History of carotid artery stenting
31 (36.0)History of peripheral arterial diseasec
aVerhage scale: (1) <6 years of primary education, (2) finished 6 years of primary education, (3) 6 years primary education and <2 years of low level
secondary education, (4) 4 years of low level secondary education, (5) 4 years of average level secondary education, (6) 5 years of high level secondary
education, (7) university degree [17].
bMyocardial infarction, surgery or endovascular treatment for coronary artery disease [16].
cAny arterial occlusion or surgical intervention of a peripheral artery (eg, abdominal or leg artery).
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Physical examination included blood pressure measurement,
height (centimeters), weight (kilograms), and BMI. Neurological
examination was performed with special attention for higher
cortical functions, focal deficits, extrapyramidal signs, balance,
gait, primitive reflexes, and postural reaction.
Cognitive Assessment
Cognitive Screening and Education
We used the Dutch version of the Mini-Mental State
Examination (MMSE; maximum score of 30) as a cognitive
screening test [18]. Furthermore, the cognitive and
self-contained part of the Cambridge Examination for Mental
Disorders of the Elderly (CAMCOG; maximum score of 107)
was performed [19]. Level of education was defined according
to a 7-point rating scale (Verhage scale 1-7; low to high
education) [17]. The severity of cognitive symptoms was
assessed using the Clinical Dementia Rating (CDR; 0-3) global
score [20].
Psychological Assessment and Other Questionnaires
Neuropsychiatric and behavioral symptoms were evaluated by
the 15-item Geriatric Depression Scale (GDS) [21] and the
Neuropsychiatric Inventory (NPI; maximum score of 144) [22].
The Disability Assessment for Dementia (DAD; maximum score
of 100) questionnaire investigated functional decline [23]. The
NPI and DAD were collected through the use of a
proxy-respondent. Table 3 shows the cognitive and
psychological screening scores at baseline.
Table 3. Cognitive and psychological assessment in the TRACE-VCI population (N=861).
Median (IQR)n (%)Instruments/methods
Global functioning
89 (75-98)738 (85.7)DAD
Mood
3 (2-5)815 (94.7)GDS
10 (4-19)604 (70.2)NPIa
Measures of global cognitive status
0.5 (0.5-1)861 (100)CDR
25 (22-28)856 (99.4)MMSE score
82 (69-91)698 (81.1)cCAMCOGb
aA higher NPI score relates to more neuropsychiatric symptoms.
bReference values of the CAMCOG score depend on primary education level and age.
cThe outpatient memory clinic of the UMCU did not perform the CAMCOG, and the VCI outpatient clinic of the UMCU introduced it at a later stage;
therefore, 163 (18.9%) were missing
Neuropsychological Assessment
All participants performed an extensive neuropsychological
examination, with some variation between the centers and over
time. This battery has been established through a Dutch
multicenter university memory clinic research program on
diagnosis and prognosis of cognitive impairment and dementia
[8]. Only tasks that were available by the majority of patients
(>80%) were included. The tasks were summarized in five major
widely used cognitive domains to reduce the amount of
neuropsychological variables for statistical analysis and clinical
interpretation: (1) working memory, (2) memory, (3) attention
and executive functioning, (4) processing speed, and (5)
perception and construction. The tests included in each of the
domains are listed in Table 4.
The domain working memory was assessed by the Digit Span
of the Wechsler Adult Intelligence Scale – 3rd edition
(WAIS-III). Patients were asked to verbally repeat series of
digits of increasing length in forward and backward condition.
The domain memory was assessed by the Dutch version of the
Rey Auditory Verbal Learning Test (RAVLT). For the RAVLT,
the total number of words remembered in five learning trials
was recorded and the delayed recall and recognition tasks were
used. Furthermore, the Visual Association Test (VAT) part A
was included to assess visuospatial association learning.
The domain attention and executive functioning was assessed
using the ratio of the Trail Making Test part B and A (TMT-B
and TMT-A), the Stroop Color Word Test, and the category
naming tasks (animal naming, 1 minute) and lexical fluency
tasks (letters, 1 minute). The used letters in the lexical fluency
tasks were different between the clinics. The letters “N” and
“A” were used in 66 patients of the VCI outpatient clinic
UMCU. The letters “D,” “A,” and “T” were used in 626 patients
of the Amsterdam Dementia Cohort VUMC. The total number
of correct responses was recorded and averaged over the
evaluated amount of letters.
The domain information processing speed was assessed by the
TMTA-A, the Stroop Color Word Test I and II, and the Digit
Symbol-Coding Test (DSCT) of the WAIS-III or the Letter
Digit Substitution Test (LDST). In both the DSCT and the
LDST, patients were asked to copy as many symbols or digits
according to a code key in a specific amount of time. The DSCT
was performed in 65 patients and the LDST in 696 patients.
The difference in time (60 vs 90 seconds) was resolved by the
use of Z scores for each version in the creation of the cognitive
domain.
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Table 4. Neuropsychological test scores and cognitive domains in the study population (N=861).
Raw test scores,
mean (SD)
Patients,
n (%)
Neuropsychological tests and cognitive domains
721 (83.7)Working memory
5.4 (1.1)715 (83.0)WAIS-III Digit Span forward [24]
4.0 (1.0)721 (83.7)WAIS -III Digit Span backward
854 (99.2)Memory
28.9 (11.5)815 (94.7)RAVLT trials 1-5 [25]
8.9 (3.7)783 (90.9)VAT part A [26]
4.3 (3.8)810 (94.1)RAVLT delayed recall
25.0 (4.1)806 (93.6)RAVLT recognition
848 (98.5)Attention and executive functioning
3.1 (1.4)635 (73.8)Ratio TMTA part B/TMT part A [27]
1.2 (0.4)729 (84.7)Stroop Color Word Test III/(I and II) [28]
15.0 (6.6)833 (96.7)Category fluency (Animals) [29]
Letter fluency [29]
17.5 (7.8)66 (7.6)N+A
26.8 (13.2)626 (72.7)D+A+T
837 (97.2)Information processing speed
72.0 (55.2)792 (92.0)TMTA part A
60.3 (25.5)796 (92.5)Stroop Color Word Test I
86.2 (40.6)788 (91.5)Stroop Color Word Test II
WAIS-III [24]
42.0 (15.2)65 (7.5)SDMT
33.1 (12.7)696 (80.8)LDST
705 (81.9)Perception and construction
17.4 (4.0)696 (80.8)Incomplete Letters
9.3 (1.3)682 (79.2)Dot Counting
The cognitive domain perception and construction was made
using the Visual Object and Space Perception Battery,
administering two separate tests known as the Incomplete Letters
and Dot Counting. The numbers of correct responses were
recorded.
Z scores were created for each individual test (reversed Z scores
for the TMT and Stroop Color Word Test). The test Z scores
were averaged to create domain Z scores. If patients were unable
to perform a test for various reasons, the test was defined as a
missing variable. Where applicable, reports on the TRACE-VCI
study will report proportions of subjects with missing values
and explore potential biases. If individual test scores were
missing, the domain Z score was based only on the available
tests.
Laboratory Testing
Plasma fasting or nonfasting glucose level, cerebrospinal fluid
(CSF), and DNA for apolipoprotein E (APOE) genotyping were
collected in a subset of the study population. Collection of CSF
biomarkers is not a standard procedure in memory clinics in the
Netherlands, but in our centers it is performed quite frequently,
at the discretion of the doctor and the patient. CSF
concentrations of amyloid B 1-42 (Aβ42), tau and/or total tau
phosphorylated at threonine 181 (p-tau) were measured at a
central laboratory for clinics at the Department of Clinical
Chemistry of the VUMC in 62.8% (541/861) of patients [30].
In 51.6% (444/861) of patients, APOE genotyping was
performed. For APOE genotyping, DNA was isolated from
10ml ethylenediamine tetraacetic acid blood. Subjects were
classified as APOE e4 carriers if they had one or two e alleles
and as noncarriers if they had no e4 alleles.
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Table 5. Brain MRI acquisition in the study population (N=861).
Patients,
n (%)
Field strength (Tesla)Model
GE Medical Systems
71 (8.2)1.5Signa HDxt
475 (55.2)3.0Signa HDxt
73 (8.5)3.0Discovery MR 750
Philips Medical Systems
44 (5.1)3.0Ingenuity
152 (17.7)3.0Ingenia
40 (4.6)3.0Achieva
6 (0.7)Othersa
a1.5 Tesla GE Medical Systems Signa Excite, n=1 (0.1%); 1.5 Tesla Philips Medical Systems Achieva, n=2 (0.2%); 1.5 Tesla Philip Medical Systems
Intera, n=1 (0.1%); 1.5 Tesla Sonata Siemens, n=2 (0.2%).
MRI Assessment
Brain MRI Scan
Brain MRI scans were performed on a 3.0 Tesla (94.1%,
810/861) or 1.5 Tesla MRI scanner (5.9%, 51/861). Most scans
were performed on a GE (72.0%, 620/861) or Philips (27.8%,
239/861) MRI scanner (Table 5). The MRI scan protocol
included the following sequences: 3D T1-weighted,
T2-weighted, T2*-weighted/susceptibility-weighted imaging
(SWI) and fluid-attenuated inversion recovery (FLAIR)
sequences. A total of 850 (98.7%) patients were scanned using
all of these sequences. In 11 patients (1.3%), a 2D T1-weighted
sequence was acquired instead of a 3D T1-weighted sequence
and/or no FLAIR sequence was available.
The MRI sequence parameters were as follows:
• 1.5 Tesla GE Signa HDxt—3D T1-weighted sequence (172
slices, voxel size: 0.98x0.98x1.50 mm3, Repetition Time
(TR)/Echo Time (TE): 12.3/5.2 ms), 3D FLAIR sequence
(128 slices, voxel size: 1.21x1.21x1.30 mm3,
TR/TE/Inversion Time (TI): 6500/117/1987 ms), 2D
T2-weighted sequence (48 slices, voxel size: 0.98x0.98x3.00
mm3, TR/TE: 1000/23.9 ms), 2D T2*-weighted sequence
(48 slices, voxel size: 0.98x0.98x3,00 mm3, TR/TE: 1000/24
ms)
• 3.0 Tesla GE Signa HDxt—3D T1-weighted sequence (176
slices, voxel size: 0.94x0.94x1.00 mm3, TR/TE: 7.8/3.0
ms), 3D FLAIR sequence (132 slices, voxel size:
0.98x0.98x1.2 mm3, TR/TE/TI: 8000/126/2340), 2D
T2-weighted sequence (48 slices, voxel size: 0.49x0.49x3.00
mm3, TR/TE/: 8610/112 ms), 3D SWI sequence (48 slices,
voxel size: 0.49x0.49x3.00 mm3, TR/TE: 31/25 ms)
• 3.0 Tesla GE Discovery MR 750—3D T1-weigthed
sequence (176 slices, voxel size: 0.94x0.94x1.00 mm3,
TR/TE: 8.2/3.2 ms), 3D FLAIR sequence (160 slices, voxel
size: 0.98x0.98x1.2 mm3, TR/TE/TI: 8000/130/2340 ms),
2D T2-weighted sequence (48 slices, voxel size:
0.49x0.49x3.00 mm3, TR/TE/: 8300/112 ms), 3D SWI
sequence (44 slices, voxel size: 0.49x0.49x3.00 mm3,
TR/TE: 31/25 ms)
• 3.0 Tesla Philips Ingenuity—3D T1-weighted sequence
(180 slices, voxel size: 0.87x0.87x1.00 mm3, TR/TE: 9.9/4.6
ms, 3D FLAIR sequence (321 slices, voxel size:
1.04x1.04x0.56 mm3, TR/TE/TI: 4800/279/1650 ms), 2D
T2-weighted sequence (45 slices, voxel size: 0.49x0.49x3.3
mm3, TR/TE: 2500-5000/100 ms, 3D SWI sequence (247
slices, voxel size: 0.43x0.43x0.60 mm3, TR/TE: 29x20 ms)
• 3.0 Tesla Philips Achieva and Ingenia—3D T1-weighted
sequence (192 slices, voxel size: 1.00x1.00x1.00 mm3,
TR/TE: 7.9/4.5 ms), 2D FLAIR sequence (48 slices, voxel
size: 0.96x0.95x3.00 mm3, TR/TE/TI: 11000/125/2800 ms),
2D T2-weighted sequence (48 slices, voxel size:
0.96x0.96x3.00 mm3, TR/TE/TE2: 3198/140 ms), 2D
T2*-weighted sequence (48 slices, voxel size:
0.96x0.96x3.00 mm3, TR/TE: 1653/20 ms)
Visual MRI Ratings
Medial temporal lobe atrophy (MTA) was visually rated
(possible range of scores for each side, 0-4) on reconstructions
(perpendicular to the long axis of the hippocampus) of the 3D
T1-weighted images [31]. White matter hyperintensities (WMH)
were rated using the Fazekas scale (WMH grade 0-3: none or
a single punctate lesion, multiple punctate lesions, beginning
confluence of lesions, large confluent lesions) on the FLAIR
images [13]. Lacunar infarct(s), (sub)cortical infarct(s),
microbleed(s), and intracerebral hemorrhage(s) were all rated
in line with the STRIVE (Standards for Reporting Vascular
Changes on Neuroimaging) criteria [12]. Ratings were
performed by or under supervision of a neuroradiologist (in
training).
Image Processing
Despite heterogeneity in MRI acquisition, we will obtain
volumetric brain measures for all subjects. Total brain volume,
white and gray matter volume, CSF volume, intracranial volume,
and WMH volume will be calculated for all subjects, using the
3D T1-weighted sequences. We are currently evaluating
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automated image processing methods that can best accommodate
differences in acquisition. Final methods will be selected based
on accuracy across the different types of MRI acquisitions and
robustness across field strength [32,33].
Clinical Diagnosis
Clinical diagnoses were established at multidisciplinary
consensus meetings after the 1-day memory clinic evaluation
at participating centers. Diagnoses were verified by the
researchers of the TRACE-VCI project based on screening of
medical files. Patients were divided in three categories of
severity of cognitive impairment: dementia, MCI, and NOCI.
Table 6 presents the different categories.
Patients were diagnosed with dementia if there was a clear
decline in cognitive function defined as a deficit in ≥2 cognitive
domains at neuropsychological testing and interference in daily
living [4]. Dementia was further classified due to its main
etiology, based on internationally established diagnostic criteria
without knowledge of CSF biomarkers or APOE genotyping
results, in a vascular [34], neurodegenerative [35-37], or
unknown origin (Table 6).
MCI was a clinical diagnosis defined as complaints of
deterioration in cognitive function from a prior baseline and
objective evidence of impairment in at least one cognitive
domain. Instrumental activities of daily living were normal or
only mildly impaired [4].
Finally, NOCI was defined as having cognitive complaints, but
no objective cognitive impairment on neuropsychological
testing. In a memory clinic setting, such patients are also referred
to as having subjective complaints or subjective cognitive
impairment [11].
Table 6. Severity of cognitive impairment and clinical diagnosis (N=861).
Patients,
n (%)
198 (23.0)No objective cognitive impairment
213 (24.7)Mild cognitive impairment
450 (52.3)Dementia
37 (8.2)Vascular [34]
387 (85.8)Neurodegenerative
305 (78.8)Alzheimer’s disease [36]
25 (6.5)Frontotemporal dementia [37]
20 (5.2)Lewy body dementia [35]
37 (9.6)Othersa
27 (6.0)Unknown etiologyb
aSuch as Primary Progressive Aphasia [38], Cortical Basal Syndrome [39], and Progressive Supranuclear Palsy [40].
bDementia of unknown origin; further examination needed to state diagnosis.
Follow-Up Investigation
Collection of Follow-Up Data
Follow-up data were collected during a visit at the outpatient
clinic around 2 years from baseline visit. At the baseline visit,
the doctor and patient decided if a follow-up visit was necessary
and in the best interest of the patient. All patients who did not
attend the outpatient clinic after approximately 2 years were
contacted by phone and a close relative or friend was also
contacted to complement the information. If patients could not
provide information themselves, only close relatives of friends
were interviewed. If patients were unreachable or gave no
permission to contact them personally in the future, the general
practitioner or doctor of the nursing home was contacted if
permitted by informed consent at baseline visit.
Primary Outcome Measure of Prognostic Studies
The primary goal of the prognostic studies of the TRACE-VCI
study is to identify which patients have a poor clinical outcome
in the years following the initial visit. We therefore defined a
composite primary outcome measure that is robust, clinically
relevant, and could also be collected from patients who did or
could not visit the outpatient clinic again after 2 years.
Follow-up was not collected from patients with a low MMSE
[22] score of <20 or a CDR [25] of >1 at baseline visit. This
included 150 (17.4%) of all patients who were included at
baseline.
For the primary prognostic analyses in the TRACE-VCI study,
poor clinical outcome was defined as a composite of (1) marked
cognitive decline, (2) occurrence of a major vascular event, and
(3) death. Marked cognitive decline was defined as a change in
CDR of ≥1 and/or institutionalization due to cognitive
dysfunction during the follow-up period [41]. Occurrence of a
major vascular event during follow-up was defined as a stroke,
myocardial infarction, or clinical manifestations of arterial
disease requiring surgical or endovascular intervention (eg, a
coronary bypass operation, carotid artery stenosis, arterial dotter
procedure, or stent placement).
Additional Follow-Up Measurements
During the outpatient follow-up visit and by telephone contact,
additional follow-up information was collected. The
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standardized DAD questionnaire was collected from a
proxy-respondent [23]. The opinion of the patient and
proxy-respondent on progression, stability, or improvement of
cognitive symptoms was recorded. Noncognitive outcome
information collected during the outpatient clinical visit or by
telephone contact included the use of a walking aid, walking
distance, number of falls, and the possible related injury.
Relevant changes in medical history were also recorded in the
database.
The majority of patients who had an outpatient follow-up visit
also underwent an extensive neuropsychological examination.
Cognitive domains were recreated by the use of Z scores, using
the same tests as on baseline visit evaluating changes in the
different cognitive domains.
Statistical Analysis
Sample Size Considerations
The TRACE-VCI study was designed to address several research
questions. Therefore, statistical power is not a unitary construct
for the study. Overall, the total cohort of 861 subjects will allow
exploration of prognostic models including up to 10 predictors,
at a power of 0.8, to detect small effect sizes (Cohen’s d=0.2
and f2=0.02)
Planned Analysis
For the first aim—establishing clinical features of different
patterns of brain injury—cross-sectional analysis on baseline
will be performed on all subjects. Regression analyses will be
used with adjustments for age, level of education, and gender
to investigate the association between vascular brain injury and
cognitive and noncognitive outcomes. Because most injury
types are present in >100 patients (see Table 1), we will be able
to detect small to moderate effect sizes (Cohen’s d=0.2-0.4)
between groups of patients with different lesion types (power
0.8, alpha<.05). Depending on the research questions, other
covariates may be added stepwise to the model to investigate
the relation further. Factor analyses will be used to investigate
clusters of VCI phenotypes.
For the second aim, identification of key prognostic factors,
longitudinal analysis will be performed on all patients that were
eligible for follow-up (as described above). The prognostic
value of a variable will be examined using Cox proportional
hazard models. Accelerated cognitive decline, new major
vascular events, or death are the primary outcome measures.
We will start with univariate models of all possible predictors
with age, level of education, and gender as covariates.
Discussion
Principal Considerations
The TRACE-VCI study is a large prospective cohort study
evaluating the clinical features and prognosis of VCI in a
memory clinic population. The majority of previous studies on
vascular brain injury and cognition are either based on the
general population, focusing on patients who experienced a
stroke or transient ischemic attack (TIA) [7], or primarily
address one particular type of vascular brain injury, such as
WMH [42]. It is clearly important to document which clinical
phenotypes related to vascular injury can be identified in a
memory clinic setting and which factors determine prognosis
for the individual patient. With regard to clinical phenotypes,
it is important to know to which extent the type or location of
vascular injury determines the cognitive profile. This may
support a more accurate diagnosis, particularly in the context
of co-occurring neurodegenerative aetiologies, which will be
much more common in memory clinic patients than in other
populations. The TRACE-VCI study will explore these profiles
and, because of availability of CSF biomarkers in a substantial
proportion of patients, will be able to explore the interaction
between vascular brain injury and processes related to
Alzheimer’s disease. With regard to prognosis, risk factors for
cognitive dysfunction in the general population may not
necessarily determine the rate of further cognitive decline among
people attending a memory clinic. Identification of specific VCI
phenotypes in a memory clinic setting may also support selection
of patients for potential future treatment trials. The TRACE-VCI
study collected this information in the context of actual clinical
practice.
The operational definition of possible VCI as developed for the
TRACE-VCI study should be addressed in this discussion. When
the TRACE-VCI study was initiated in 2009, the construct of
VCI had been introduced [2,3], but widely accepted clinical
criteria for VCI were still lacking. We intentionally developed
nonrestrictive criteria for our study. We chose not to define
minimal thresholds for cognitive dysfunction. The rationale for
this is that patients with cognitive decline as a result of vascular
brain injury may not always develop cognitive deficits that are
severe enough to be classified as MCI. A strict method to
separate people with these more subtle cognitive changes from
patients who complain, but actually have no change in cognitive
performance at all, is not available. Hence, cognitive complaints
are the entry criterion for the TRACE-VCI study and people
without cognitive impairment are classified as NOCI, also
referred to as subjective cognitive impairment [11]. We decided
not to use the label subjective because this term has a
connotation of nonconfirmed or even psychogenic complaints
in medical practice. We did specify a minimal burden of vascular
injury because the construct of VCI requires the presence of
vascular brain injury. We deliberately did not include a criterion
on a presumed causal relation between cognitive dysfunction
and the observed vascular injury as this may in many cases rely
on assumption, while the main purpose of the TRACE-VCI
study is to determine if vascular brain injury really matters in
memory clinic patients. Importantly, we did not exclude patients
with evidence of co-occurring neurodegenerative disease as the
construct of VCI also concerns the presence of vascular as well
as neurodegenerative etiologies [3,4].
After the initiation of the TRACE-VCI study, diagnostic criteria
for VCI have been proposed by international working groups,
including criteria for Vascular Cognitive Impairment from the
American Heart Association/American Stroke Association
(AHA/ASA) [4] and criteria for vascular cognitive disorders
from the International Society of Vascular Behavioural and
Cognitive Disorders (VasCog) Society [43]. Unlike our
operational VCI criteria, both the AHA/ASA and the VasCog
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criteria define a threshold for severity of cognitive dysfunction.
When appropriate, analyses in the TRACE-VCI can be adapted
to modify these criteria by excluding people with NOCI. The
AHA/ASA criteria also apply to patients with evidence for
co-occurring neurodegenerative or other causes of cognitive
impairment, but these patients are labeled as possible VCI,
similar to our operational definition of VCI. This is different
from the VasCog criteria [43], which relates only to subjects
with evidence for predominantly vascular etiology of cognitive
impairment. The VasCog criteria consider evidence of other
etiologies, including a neurodegenerative disorder, as an
exclusion criterion for the diagnosis VCI. With regard to the
causality of the relation between cognitive dysfunction and
vascular injury, the AHA/ASA criteria distinguish between
probable and possible VCI. Probable VCI is diagnosed when a
clear temporal relationship between a vascular event (eg, a
clinical stroke) and onset of cognitive deficits is present or if
there is a clear relationship in the severity and pattern of
cognitive impairment and the presence of diffuse subcortical
cerebrovascular disease pathology (eg, as in cerebral autosomal
dominant arteriopathy with subcortical infarcts and
leukoencephalopathy). This temporal relationship is also
recorded in the TRACE-VCI database, and we can apply these
AHA/ASA criteria also in our dataset.
A key objective of TRACE-VCI is to identify prognostic factors
in patients with VCI. To this end, we wanted to define a
clinically meaningful outcome measure that we could collect
in the majority of patients and also in those who could or would
not revisit the clinic for follow-up. We chose a composite
measure that reflects the primary poor outcome of VCI: marked
cognitive decline, a major vascular event, or death. We did
perform repeated cognitive assessments in patients who attended
the outpatient clinic again, and we will perform analyses on
these dates. However, we decided not to base our definition of
marked cognitive decline on these assessments as that would
induce substantial attrition.
Strengths and Limitations
A strength of the TRACE-VCI study is that it addresses the
clinical features and prognosis of VCI in a memory clinic
setting. It thus fills a knowledge gap, as there are few available
cohort studies of VCI in this particular setting [7]. As a
consequence, despite the fact that vascular brain injury on MRI
is a very common finding in memory clinic patients, uncertainty
can exist about its clinical and prognostic relevance in individual
cases. TRACE-VCI includes a large cohort of memory clinic
patients with 2-year follow-up and detailed data on cognitive
performance, imaging markers, and comorbid conditions. A
potential weakness of our study is that patients were included
at tertiary referral centers, which may affect generalizability of
the findings. Moreover, although patients were evaluated in a
standardized fashion, the study does rely on data collection in
the context of clinical care. Therefore, there is some
heterogeneity in data acquisition (eg, MRI protocols) and not
all parameters are available for all participants. Where
applicable, reports on the TRACE-VCI study will specify
proportions of subjects with missing values and explore potential
biases. Finally, aspects of medical history (eg, vascular events)
were based on self-report, which could be affected by recall
bias. Yet, in our clinics the information is verified with an
informant (eg, relative) and the information provided by the
referring physician. Moreover, all patients bring a medication
list provided by their pharmacy, and this is also scrutinized by
the treating physician to identify relevant comorbidities.
Conclusion
The follow-up of our study is nearly complete, and data-cleaning
and processing are in progress. The TRACE-VCI cohort study
will provide detailed information on the phenotypes of VCI in
a memory clinic setting to reveal the progression of cognitive
decline and identify prognostic factors.
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CSF: cerebrospinal fluid
DAD: Disability Assessment for Dementia
DSCT: Digit Symbol-Coding Test
FLAIR: fluid-attenuated inversion recovery
GDS: Geriatric Depression Scale
LDST: Letter Digit Substitution Test
MCI: mild cognitive impairment
MMSE: Mini-Mental State Examination
MTA: medial temporal lobe atrophy
NOCI: no cognitive impairment
NPI: Neuropsychiatric Inventory
p-tau: total tau phosphorylated at threonine 181
RAVLT: Rey Auditory Verbal Learning Test
STRIVE: Standards for Reporting Vascular Changes on Neuroimaging
SWI: susceptibility-weighted imaging
TMT: trail making test
TR/TE/TI: Repetition Time/Echo Time/Inversion Time
TRACE-VCI: Utrecht Amsterdam clinical features and prognosis in vascular cognitive impairment
UMCU: University Medical Centre Utrecht
VasCog: International Society of Vascular Behavioural and Cognitive Disorders
VAT: Visual Association Test
VCI: vascular cognitive impairment
VUMC: VU (Vrije (Free)) University Medical Centre
WAIS-III: Wechsler Adult Intelligence Scale – 3rd edition
WMH: white matter hyperintensities
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